Oral 5-Aminosalicylate, Mesalamine Suppository, and Mesalamine Enema as Initial Therapy for Ulcerative Proctitis in Clinical Practice with Quality of Care Implications

Table 3

Cumulative number of study subjects experiencing treatment escalation, by duration of follow-up and treatment group.

Treatment group	Month 3		Month 6		Month 9		Month 12
	(%)	95% CI (%)	(%)	95% CI (%)	(%)	95% CI (%)	(%)	95% CI (%)
Oral 5-ASA ()	29 (21.0)	(14.2, 27.8)	37 (26.8)	(19.4, 34.2)	42 (30.4)	(0.3, 22.8)	47 (34.1)	(26.2, 42.0)
Mesalamine suppository ()	31 (9.5)	(6.3, 12.7)	52 (15.9)	(11.9, 19.9)	59 (18.0)	(0.2, 13.9)	68 (20.8)	(16.4, 25.2)
Mesalamine enema ()	10 (12.0)	(5.0, 19.1)	15 (18.1)	(9.8, 26.4)	17 (20.5)	(0.2, 11.8)	17 (20.5)	(11.8, 29.2)

Oral 5-ASA: oral 5-aminosalicylate.